Company Description
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction.
Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.
The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence.
It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally.
The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021.
Axonics, Inc. was incorporated in 2012 and is based in Irvine, California. As of November 15, 2024, Axonics, Inc. operates as a subsidiary of Boston Scientific Corporation.
| Country | United States |
| Founded | 2012 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 797 |
| CEO | Raymond Cohen |
Contact Details
Address: 26 Technology Drive Irvine, California 92618 United States | |
| Phone | 949 396 6322 |
| Website | axonics.com |
Stock Details
| Ticker Symbol | AXNX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001603756 |
| CUSIP Number | 05465P101 |
| ISIN Number | US05465P1012 |
| Employer ID | 45-4744083 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Raymond W. Cohen | Chief Executive Officer and Director |
| Kari Keese | Chief Financial Officer |
| Rinda K. Sama | Chief Operating Officer |
| Dr. John Woock Ph.D. | Executive Vice President, Chief Marketing and Strategy Officer |
| Alfred J. Ford Jr. | Chief Commercial Officer |
| Guangqiang Jiang Ph.D. | Chief Technology Officer |
| Neil Bhalodkar | Vice President of Investor Relations |
| Aaron Pettit | General Counsel and Chief Compliance Officer |
| Michael V. Williamson Esq., J.D. | Senior Vice President, General and IP Counsel |
| Dr. Karen L. Noblett M.A.S., M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | 25-NSE | Filing |
| Nov 15, 2024 | POS AM | Post-Effective amendments for registration statement |
| Nov 15, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Nov 15, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Nov 15, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Aug 1, 2024 | 10-Q | Quarterly Report |
| Aug 1, 2024 | 8-K | Current Report |
| Apr 30, 2024 | 10-Q | Quarterly Report |